rs6923761 gene variant in glucagon-like peptide 1 receptor: Allelic frequencies and influence on cardiovascular risk factors in a multicenter study of Castilla-Leon

Luis, Daniel Antonio de; Ballesteros, María Rosa Albañil; Guzman, A. Lopez; Ruiz, Enrique Martínez; Muñoz, Carmen; Penacho, M.A.; Iglesias, Pedro; Puigdevall, V.; Delgado, Manuel

doi:10.1016/j.clnu.2017.10.013

Cited by 11 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a multi-center study of Spanish adults, de Luis et al reported an association between WC and the SNP rs6923761, located in proximity to the glucagon-like peptide 1 receptor (GLP1R) (103). The authors acknowledge that the mechanistic link between this SNP and WC remains unclear, but suggest that it may affect adipogenesis in the abdominal VAT depot (104).…”

Section: Meta-analyses Published By the Genetic Investigation Of Anthmentioning

confidence: 99%

Determinants of body fat distribution in humans may provide insight about obesity-related health risks

Frank

Santos

Palmer

et al. 2019

Journal of Lipid Research

181

133

View full text Add to dashboard Cite

Section: Meta-analyses Published By the Genetic Investigation Of Anthmentioning

confidence: 99%

Determinants of body fat distribution in humans may provide insight about obesity-related health risks

Frank

Santos

Palmer

et al. 2019

Journal of Lipid Research

181

133

View full text Add to dashboard Cite

“…Associations of GLP1R rs6923761 polymorphism with the anthropometric parameters and metabolic traits were investigated in more detail in 341 obese subjects from the Spanish region of Castilla y Leon. Significantly higher BMI, weight, fat mass, waist to hip ratio, and waist circumference, as well as higher insulin levels and higher HOMA-IR index values, were observed in the group of subjects with the wild-type rs6923761 GG genotype as compared to carriers of one or two polymorphic A alleles [ 61 ].…”

Section: Genetic Variability Of the Incretin Systemmentioning

confidence: 99%

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors

Klen

Dolžan

2022

IJMS

View full text Add to dashboard Cite

Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of antihyperglycemic drugs that enhance appropriate pancreatic β-cell secretion, pancreatic α-cell (glucagon) suppression, decrease liver glucose production, increase satiety through their action on the central nervous system, slow gastric emptying time, and increase insulin action on peripheral tissue. They are effective in the management of type 2 diabetes mellitus and have a favorable effect on weight loss. Their cardiovascular and renal safety has been extensively investigated and confirmed in many clinical trials. Recently, evidence has shown that in addition to the existing approaches for the treatment of obesity, semaglutide in higher doses promotes weight loss and can be used as a drug to treat obesity. However, some T2DM and obese patients do not achieve a desired therapeutic effect of GLP-1 receptor agonists. This could be due to the multifactorial etiologies of T2DM and obesity, but genetic variability in the GLP-1 receptor or signaling pathways also needs to be considered in non-responders to GLP-1 receptor agonists. This review focuses on the pharmacological, clinical, and genetic factors that may influence the response to GLP-1 receptor agonists in the treatment of type 2 diabetes mellitus and obesity.

show abstract

“…Previous studies have shown that GLP1R polymorphisms are associated with susceptibility to diabetes and clinical responsiveness to different hypoglycemic agents [13] . Moreover, GLP1R polymorphisms are associated with lipid metabolism and the risk of coronary artery disease in T2DM patients [14] . However, the relationship between GLP1R gene polymorphisms and the onset age of T2DM has not yet been established.…”

Section: Introductionmentioning

confidence: 99%

GLP1R Rs3765467 Polymorphism Is Associated With The Risk Of Early-Onset Type 2 Diabetes

Fang

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective: To investigate the relationship between glucagon-like peptide-1 receptor (GLP1R) gene polymorphisms and susceptibility to early-onset type 2 diabetes (EOD).Methods: Samples from 316 type 2 diabetes (T2DM) patients with EOD (n = 137) and late-onset T2DM (n = 179) and 145 non-diabetic individuals were analyzed. Multiplex PCR combined with resequencing HI-Reseq technology was used to detect single nucleotide polymorphisms (SNPs) of the GLP1R gene, and the allele frequency, genotype distribution, and clinical parameters were analyzed between each diabetes subgroup and the control group.Results: Sixteen SNPs were identified in the exonic region of the GLP1R gene according to the minor allele frequency (MAF > 0.05) in the participants. Among these, the GLP1R rs3765467 (G→A) mutation was statistically associated with EOD. Compared with that of the GG carriers, carriers of genotype AA at rs3765467 had a decreased risk of EOD after adjusting for sex and body mass index. In the dominant model, the frequencies of the rs3765467 AA+GA genotype were significantly decreased in the EOD group, and carriers of genotype AA+GA at rs3765467 had a decreased risk of EOD after adjusting for sex and body mass index. Moreover, fasting c peptide levels were significantly higher in GA+AA genotype carriers than that in GG genotype carriers.Conclusion: The GLP1R rs3765467 polymorphism was significantly associated with the age at T2DM diagnosis, and thus may be used as a marker to screen and detect individuals at risk of developing EOD.The name of the clinical trials registry: Exploration of early warning indicators for diabetic chronic complications. The approval number is 2016-004.The approval date is June 12, 2016.

show abstract

rs6923761 gene variant in glucagon-like peptide 1 receptor: Allelic frequencies and influence on cardiovascular risk factors in a multicenter study of Castilla-Leon

Cited by 11 publications

References 23 publications

Determinants of body fat distribution in humans may provide insight about obesity-related health risks

Determinants of body fat distribution in humans may provide insight about obesity-related health risks

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors

GLP1R Rs3765467 Polymorphism Is Associated With The Risk Of Early-Onset Type 2 Diabetes

Contact Info

Product

Resources

About